EUVIMEDEUVIMED entdecken
Crossref

Letter to the Editor: Patient-reported outcomes of intensity-modulated radiotherapy vs three-dimensional conformal radiotherapy in prostate cancer

Melek Yakar

World Journal of Clinical Oncology · 24.07.2026 · 17 (7)

DOI: 10.5306/wjco.120006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Clinical Oncology, online erschienen am 24.07.2026. Verfasst von Melek Yakar. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, published in the World Journal of Clinical Oncology by Mera et al , three-dimensional conformal radiotherapy and intensity-modulated radiotherapy were assessed with respect to patient-reported outcome measures in patients with localized prostate cancer. Furthermore, they used a prospective observational design and analyzed urinary, gastrointestinal, sexual, and quality-of-life end points using real-world outcomes, as opposed to dose-volume histograms or clinician-based toxicity scales. They use the patient-reported outcome measures to show how patients perceive radiotherapy technique, fractionation, dose escalation, and technology.

Zitieren

APA

Yakar, M. (2026). Letter to the Editor: Patient-reported outcomes of intensity-modulated radiotherapy vs three-dimensional conformal radiotherapy in prostate cancer. World Journal of Clinical Oncology, 17(7). https://doi.org/10.5306/wjco.120006

Vancouver

Yakar M. Letter to the Editor: Patient-reported outcomes of intensity-modulated radiotherapy vs three-dimensional conformal radiotherapy in prostate cancer. World Journal of Clinical Oncology. 2026;17(7). doi:10.5306/wjco.120006

BibTeX
@article{Yakar2026,
  author = {Yakar, Melek},
  title = {Letter to the Editor: Patient-reported outcomes of intensity-modulated radiotherapy vs three-dimensional conformal radiotherapy in prostate cancer},
  journal = {World Journal of Clinical Oncology},
  year = {2026},
  volume = {17},
  number = {7},
  doi = {10.5306/wjco.120006}
}
Kostenlos starten →